Filed under: Investing
In this segment of the Motley Fool's Market Check-Up, Fool health-care analyst David Williamson takes investors through some of the biggest stories affecting Big Pharma, biotech stocks, and the health insurance industry today.
Bristol-Myers Squibb has announced it will be divesting itself of its joint diabetes franchise that it held with AstraZeneca , selling its portion back to AZN for $2.7 billion, plus a milestone payment of $700 million if the sodium-glucose transport protein SGLT2 drug Forxega, focused on the treatment of diabetes, is approved. David discusses the likelihood of Forxega approval, and what this could mean both for Bristol-Myers Squibb, and for AstraZeneca, as well as why it is important as an investor to be thinking long-term about Bristol-Myers when looking at this deal today.
Two game-changing biotechs
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report, "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
The article Diabetes Drug Partnership Amicable Divorce originally appeared on Fool.com.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
Read | Permalink | Email this | Linking Blogs | Comments